Weight-Loss Induced Changes in Plasma Factor VII Coagulant Activity and Relation to the Factor VII Arg/Gln₃₅₃ Polymorphism in Moderately Obese Adults

Summary

Elevated plasma factor VII coagulant activity (factor VIIc) may be an independent risk factor for coronary heart disease. Several cross-sectional studies suggest that a polymorphism of the factor VII gene (ArgGln₃₅₃) interacts with plasma triglyceride level in determining factor VIIc, but prospective data are lacking. Factor VII genotype, factor VIIc, and triglyceride level were measured in moderately obese adults aged 25 to 45 who underwent a six-month clinical trial to evaluate strategies for weight loss. A total of 48 men and 50 women who experienced substantial weight loss (mean: 10 kg) provided samples for genetic analysis. Overall, 78% of participants were homozygous for the Arg₃₅₃ allele, while the remaining 22% were heterozygous (Arg/Gln₃₅₃). At the baseline examination, heterozygotes had lower mean factor VIIc than Arg₃₅₃ homozygotes (92% vs. 112%; p<0.001), and genotype explained 18% of the variance of factor VIIc. Average six-month weight loss was similar in both genotypes; mean reductions in factor VIIc following weight loss were greatest among Arg₃₅₃ homozygotes with high initial values (>120%). Cross-sectional and longitudinal associations between plasma factor VIIc and triglyceride level were not dependent on genotype. These data confirm that the Gln₃₅₃ allele is associated with lower factor VII coagulant activity in moderately obese adults, but they do not support the hypothesis that the Arg-Gln₃₅₃ polymorphism interacts with plasma triglyceride level in determining factor VIIc.

• References

• 1 Morrissey JH. Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coagul Fibrinolysis 1995; 6 (Suppl. 01) S14-S9.
• 2 Meade TW. Haemostatic function, arterial disease and the prevention of arterial thrombosis. Ballieres Clin Haematol 1994; 7: 733-55.
• 3 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 4 Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Münster Heart Study (PROCAM). Isr J Med Sci 1996; 32: 364-70.
• 5 Folsom AR, Wu KK, Rosamond WD, Sharett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
• 6 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
• 7 Lane A, Cruickshank JK, Mitchell J, Henderson A, Humphries S, Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. Atherosclerosis 1992; 94: 43-50.
• 8 Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-8.
• 9 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen as risk factors for venous thrombosis. Thromb Haemost 1994; 71: 719-22.
• 10 Saha N, Liu Y, Heng CK, Hong S, Low PS, Tay JSH. Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglyceride. Arterioscler Thromb 1994; 14: 1923-7.
• 11 Kario K, Narita N, Matsuo T, Kayaba K, Tsutsumi A, Matsuo M, Miyata T, Shimada K. Genetic determinants of plasma factor VII activity in the Japanese. Thromb Haemost 1995; 73: 617-22.
• 12 Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-9.
• 13 Meilahn E, Ferrell R, Kiss J, Temple A, Green F, Humphries S, Kuller L. Genetic determination of coagulation factor VIIc levels among healthy middle-aged women. Thromb Haemost 1995; 73: 623-5.
• 14 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with MI at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
• 15 Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.
• 16 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocar-dial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
• 17 Humphries S, Temple A, Lane A, Green F, Cooper J, Miller G. Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Thromb Haemost 1996; 75: 567-72.
• 18 Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94: 2171-6.
• 19 Heywood DM, Mansfield MW, Grant PJ. Factor VII gene polymorphisms, factor VII:c levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 75: 401-6.
• 20 Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVII:c levels in relation to acute cerebrovascular disease and poststroke mortality. Stroke 1997; 28: 816-21.
• 21 Wing RR, Jeffery RW, Burton LR, Thorson C, Kuller LH, Folsom AR. Change in waist-hip ratio with weight loss and its association with change in cardiovascular risk factors. Am J Clin Nutr 1992; 55: 1086-92.
• 22 Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-9.
• 23 Paffenbarger Jr RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol 1978; 108: 161-75.
• 24 Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
• 25 Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-82.
• 26 Warnick GR, Albers JJ. A comprehensive evaluation of the heparinmanganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978; 19: 65-76.
• 27 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 28 Herbert V, Lau KS, Gottlieb CW. Coated charcoal immunoassay of insulin. J Clin Endocrinol 1965; 25: 1375-4.
• 29 Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-16.
• 30 Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. 2nd ed. PWS-Kent; Boston, MA: 1988. pp 271-2.
• 31 Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Genetic aspects of susceptibility to obesity and related dyslipidemias. Mol Cell Biochem 1992; 113: 151-69.
• 32 Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996; 16: 1333-9.
• 33 Miller GJ. Lipoproteins and the haemostatic system in atherothrombotic disorders. Ballieres Clin Haematol 1994; 7: 713-1.
• 34 Pollak ES, Hung H-L, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5’ flanking region. J Biol Chem 1996; 271: 1738-47.
• 35 Sacchi E, Tagliabue L, Scoglio R, Baroncini C, Coppola R, Bernardi F, Mannucci PM. Plasma factor VII levels are influenced by a polymorphism in the promoter region of the FVII gene. Blood Coag Fibrinol 1996; 7: 114-7.
• 36 Niskanen L, Schwab US, Sarkkinen ES, Krusius T, Vahtera E, Uusitupa MIJ. Effects of dietary fat modification on fibrinogen, factor VII, and plasminogen activator inhibitor-1 activity in subjects with impaired glucose tolerance. Metabolism 1997; 46: 666-72.
• 37 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
• 38 Kario K, Matsuo T, Asada R, Sakata T, Kato H, Miyata T. The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level. Thromb Haemost 1995; 73: 429-34.